237 related articles for article (PubMed ID: 33032292)
21. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
22. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
23. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
[TBL] [Abstract][Full Text] [Related]
24. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S
Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662
[TBL] [Abstract][Full Text] [Related]
27. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel.
Krakowski AC; Nguyen TA
Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829
[TBL] [Abstract][Full Text] [Related]
29. Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Gau SY; Chen SL; Chang CS; Tsao TF; Tsai JD
Int J Med Sci; 2023; 20(10):1358-1362. PubMed ID: 37786437
[No Abstract] [Full Text] [Related]
30. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
[TBL] [Abstract][Full Text] [Related]
31. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
32. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
Zipori AB; Tehrani NN; Ali A
J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
[TBL] [Abstract][Full Text] [Related]
33. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
34. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
35. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
Yalon M; Ben-Sira L; Constantini S; Toren A
Childs Nerv Syst; 2011 Jan; 27(1):179-81. PubMed ID: 20703486
[TBL] [Abstract][Full Text] [Related]
36. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.
Franz DN
Biologics; 2013; 7():211-21. PubMed ID: 24143074
[TBL] [Abstract][Full Text] [Related]
37. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
38. Safety and Effectiveness of Medical Therapy and Surgical Intervention for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Wang Z; Zhang W; Fan Y; Zhang X
Cancer Control; 2022; 29():10732748221140266. PubMed ID: 36471546
[TBL] [Abstract][Full Text] [Related]
39. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
[TBL] [Abstract][Full Text] [Related]
40. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.
Hatano T; Inaba H; Endo K; Egawa S
Int J Urol; 2017 Nov; 24(11):780-785. PubMed ID: 28905429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]